1034890-95-3

Upstream product

• 30170-62-8 1-(4-cyclopropylphenyl)propan-1-one 
• 75716-82-4 imidazol-1-yl-oxo-acetic acid ethyl ester 

Downstream Products

• 1170061-72-9 5-(4-cyclopropylphenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 1170061-90-1 C₂₂H₂₀ClFN₂O₂ 
• 1170061-96-7 C₂₂H₂₀ClFN₂O₂ 
• 1170062-02-8 C₂₂H₂₀BrClN₂O₂ 
• 1170061-94-5 C₂₂H₂₂N₂O₂ 
• 1170061-98-9 C₂₂H₂₁ClN₂O₂ 
• 1170061-86-5 C₂₂H₂₁FN₂O₂ 
• 1170061-91-2 C₂₂H₂₁FN₂O₂ 
• 1170061-88-7 C₂₂H₂₁ClN₂O₂ 
• 1170061-83-2 C₂₂H₂₀F₂N₂O₂ 

Relevant academic research and scientific papers

Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists

Obesity is a major clinical problem in the western world, and many molecular targets have been explored in the search for effective therapeutic agents. One of these, antagonism of the cannabinoid 1 (CB1) receptor, rose to prominence following reports demo

NOVEL CB1 ANTAGONISTS AND THEIR PREPARATION

The invention relates to new compounds of general formula (I) acting as CB1 antagonists and to their preparation. The compounds according to this invention can be used for the treatment of obesity, behavioral addictions, psychiatric and metabolic disorder